Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety of Viekira, as well as its place in hepatitis C virus (HCV) therapy, are reviewed.
T here are seven hepatitis C virus (HCV) genotypes with marked differences in global geographic distribution. 1 While different genotypes express minimal overall differences in disease progression, they exhibit clear differences in susceptibility to antiviral therapy. HCV genotype 1 is predominantly found in the United States, comprising 70-80% of HCV infections, followed by HCV genotypes 2, 3, and 4 in the order of prevalence. 2 Before the advent of second-generation direct-acting antivirals, HCV genotype 1 infections were the most difficult to eradicate in the United States. HCV genotype 1 encompasses 11 subgenotypes, with genotypes 1a, 1b, and 1c causing the majority of infections. 3 Before the emergence of directacting antiviral agents, peginterferon alfa-ribavirin therapy was the standard of care for HCV infection. For over a decade, the use of peginterferon alfa-ribavirin therapy resulted in relatively poor sustained virological response (SVR) rates, ranging from 40% to 50% for genotype 1 infections. 4, 5 SVR is defined as an undetectable HCV level in the blood during treatment and for 12 weeks after treatment completion. 6 SVR, a key response measure for treatment effectiveness, is associated with decreases in allcause mortality, liver-related death rates and complications, and hepatocellular cancer rates. 7, 8 Peginterferon alfa-ribavirin therapy is also noted to cause intolerable adverse effects and high rates of viral relapse. 4, 5, 9 The approval of the firstgeneration HCV protease inhibitors, boceprevir and telaprevir, marked a major breakthrough toward achieving higher SVR rates when used in combination with peginterferon alfaribavirin compared with peginterferon alfa-ribavirin therapy alone for patients with HCV genotype 1 infection. Both drugs inhibited the nonstructural protein 3/4A serine protease enzyme complex and were used as adjunctive therapy with peginterferon alfa-ribavirin. SVR rates varied from 70% to 80% when treatmentnaive patients were taking either boceprevir or telaprevir with peginterferon alfa-ribavirin. [10] [11] [12] However, their use was hampered by a cumbersome response-guided therapy approach, an increased pill burden, drug-drug interactions, low barriers to resistance, and notable adverse effects. [13] [14] [15] [16] More recently, newer-generation HCV direct-acting antivirals, consisting of protease inhibitors, nonstructural protein inhibitors, and RNA polymerase inhibitors, have demonstrated better pharmacologic properties, clinical efficacy, and safety profiles.
Oral, interferon-free ombitasvirparitaprevir-ritonavir plus dasabuvir (Viekira Pak, AbbVie) was approved by the Food and Drug Administration (FDA) on December 19, 2014 , for the treatment of HCV genotype 1 infected persons (treatment naive and treatment experienced), including those with compensated cirrhosis. Viekira is a standalone, fixed-dose combination regimen administered with or without ribavirin, depending on the patient's HCV subtype, cirrhosis status, and treatment experience. 17 It is the fourth agent of the newer generation of direct-acting antivirals available for patients infected with HCV genotype 1 and coinfected with human immunodeficiency virus (HIV). Viekira is currently not recommended in
KEY POINTS
• Viekira could be used in patients infected with HCV who have advanced renal impairment.
• Viekira is contraindicated for use in patients with ChildPugh class cirrhosis.
• Viekira could be used for HCV-HIV coinfected patients.
patients with decompensated cirrhosis. 17, 18 This article reviews the pharmacology, pharmacokinetics, clinical efficacy, and safety of Viekira, as well as its place in HCV therapy.
Background
HCV is prolific and produces up to 10 12 particles daily. 19 It has an enveloped, positive-sense, single-stranded RNA genetic material of approximately 9600 base pairs in length. Once inside the hepatocyte, the viral genome is released from the nucleocapsid, and the HCV polyprotein is translated via the internal ribosome. The polyprotein is cleaved by cellular and viral proteases to yield structural and nonstructural proteins. 20 The core nonstructural 3 and 5A proteins form the replication complex on lipid droplets and serve as a scaffold for the RNA polymerase to replicate the viral genome. Its genome encodes a single long polyprotein that is processed into 10 separate proteins by viral enzymes (nonstructural proteins) and cellular enzymes (structural proteins). 21 There are 4 major structural proteins and at least 6 nonstructural proteins that comprise the protease, helicase, and RNA-dependent RNA polymerase activities of the virus. [20] [21] [22] The HCV nonstructural proteins comprise the RNA replication machinery (Figure 1 ). 23 Every step in viral replication is considered a potential drug target, including RNA genome translation, assembly, and export of progeny viruses. The direct-acting antivirals include nonstructural 3/4A serine protease inhibitors, nucleoside-nucleotide and nonnucleoside inhibitors of the nonstructural 5B polymerase, and nonstructural 5A inhibitors. 24, 25 These drugs primarily target the replication, polyprotein processing, packaging in nucleocapsid, assembly, and release of HCV infectious particles. The plusstranded viral RNA is first translated into a large polyprotein that is then cleaved by host and viral proteases into structural and enzymatic proteins, respectively. 26 The small, errorprone, RNA-dependent RNA polymerase is a major transcription factor, accounting for the high mutability and rapid acquisition of resistance because it lacks proofreading ability. This genetic characteristic contributes to the virus's genetic diversity. 19 
Pharmacology
The components of Viekira target three different protein enzymes that are essential for the HCV life cycle. Ombitasvir inhibits the HCV nonstructural 5A protein complex, which is required for viral replication and assembly. Similarly, dasabuvir inhibits the HCV nonstructural 5B RNAdependent RNA polymerase, which suppresses viral replication. Paritaprevir works at a later stage of the virus's life cycle and inhibits the nonstructural 3/4A serine protease, which is required for proteolytic cleavage of the HCV-encoded polyprotein leading to mature viruses. 27 In addition, inhibition of the protease may promote innate immune signaling, which may help with viral clearance.
Ritonavir, a HIV protease inhibitor and a potent cytochrome P-450 (CYP) isozyme 3A4 inhibitor, is formulated with paritaprevir as a pharmacokinetic enhancer to increase the plasma concentrations and halflife of paritaprevir, thus allowing for once-daily dosing. 17 Ritonavir does not have any activity against HCV. The dosage and oral administration of Viekira are two tablets of fixeddose combination ombitasvir 12.5 mg-paritaprevir 75 mg-ritonavir 50 mg once daily (in the morning) and one tablet of dasabuvir 250 mg twice daily (morning and evening) with food. Dasabuvir is supplied as separate tablets and is packaged with ombitasvir-paritaprevirritonavir. When ribavirin is coadministered with Viekira, it is dosed based on the patient's weight (<75 kg = 1000 mg/day; ≥75 kg = 1200 mg/day) and given twice daily with food.
Pharmacokinetics
Ombitasvir, paritaprevir, ritonavir, and dasabuvir are well absorbed within four to five hours after oral ingestion. Relative to fasting conditions, a moderately fatty meal (ap- proximately 600 calories, 20-30% from fat) increases the mean area under the concentration-time curve (AUC) of ombitasvir, paritaprevir, ritonavir, and dasabuvir to 82%, 211%, 49%, and 30%, respectively. 18, 28 The administration of a high-fat meal (900 calories, 60% from fat) increases the mean AUC of om bitasvir, paritaprevir, ritonavir, and dasabuvir by 76%, 180%, 44%, and 22%, respectively. Therefore, the regimen should be administered with a meal. The steady-state maximum plasma concentrations for ombitasvir, paritaprevir, ritonavir, and dasabuvir are 68, 262, 682, and 667 ng/mL, respectively, after 12 days of therapy.
Ombitasvir, paritaprevir, ritonavir, and dasabuvir are highly bound to human plasma proteins (99.9%, 98.6%, 99.0%, and 99.5%, respectively). 29, 30 Ombitasvir is primarily metabolized by amide hydrolysis followed by oxidative metabolism. In contrast, paritaprevir and ritonavir are predominantly metabolized by CYP3A4. Dasabuvir is primarily metabolized by CYP2C8. 31 The mean elimination half-life of ombitasvir is approximately 21-25 hours. The mean plasma half-lives of paritaprevir and dasabuvir are approximately 5.5 and 5.5-6 hours, respectively. The mean plasma half-life of ritonavir is approximately 4 hours after its administration with ombitasvir and paritaprevir.
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The AUC values are notably affected by the severity of liver disease, suggesting the regimen should not be recommended for HCV-infected individuals with moderate hepatic impairment (Child-Pugh class B). Furthermore, the combination regimen is contraindicated in patients with severe hepatic impairment (Child-Pugh class C) due to the risk of accumulation and toxicity. 29, 30 In vivo data suggest that the changes in exposure to ombitasvir, paritaprevir, ritonavir, and dasabuvir in subjects with mild (creatinine clearance [CL cr ], 60-89 mL/min), moderate (CL cr, , 30-59 mL/min), and severe (CL cr , 15-29 mL/min) renal impairment are not clinically notable. 30, 32 Thus, no dosage adjustments are recommended for Viekira in patients with mild-to-severe renal impairment. No pharmacokinetic data are available for ombitasvir, paritaprevir, ritonavir, and dasabuvir in non-HCV-infected subjects with end-stage renal disease.
Clinical efficacy
The efficacy of Viekira with or without ribavirin was evaluated in six pivotal Phase III, randomized, multicenter trials-PEARL-II, PEARL-III, PEARL-IV, SAPPHIRE-I, SAPPHIRE-II, and TURQUOISE-II. [33] [34] [35] [36] [37] The trials enrolled more than 2300 patients with HCV genotype 1 infection with or without cirrhosis. Study patients were randomly assigned to receive Viekira or placebo with or without ribavirin for 12 or 24 weeks. Ribavirin was dosed according to body weight (<75 kg = 1000 mg/day; ≥75 kg = 1200 mg/day). Viekira was also evaluated in special populations comprised of genotype 1 infected patients with liver transplantation, coinfected with HIV, or with advanced renal disease. The primary efficacy endpoint for the clinical trials was SVR rates 12 weeks after treatment completion, or virological cure.
PEARL-II. PEARL-II was an openlabel trial that evaluated the efficacy of Viekira in 186 patients without cirrhosis with HCV genotype 1b whose disease had relapsed, partially responded, or did not respond to previous treatment with peginterferon-ribavirin therapy. 33 Patients were stratified by prior response to peginterferon alfaribavirin (relapse, partial response, or null response) and randomized in a 1:1 ratio to receive Viekira with (n = 91) or without (n = 95) ribavirin for 12 weeks. The mean SVR rate was 100% for patients who did not receive ribavirin, compared with 97% in the group receiving ribavirin. No virological failures were reported. Viekira was well tolerated, with only 2 people in the ribavirin-containing group discontinuing treatment early due to adverse events. Results from this study demonstrated that patients with genotype 1b who did not respond to peginterferon alfa-ribavirin therapy can achieve very high cure rates with an oral peginterferon alfa-free regimen without ribavirin.
PEARL-III and PEARL-IV. The PEARL-III and PEARL-IV trials were similar in design. 34 These doubleblind, placebo-controlled trials evaluated the efficacy of Viekira, with or without ribavirin, for 12 weeks in treatment-naive patients without cirrhosis. Patients were randomized to receive either ribavirin or matching placebo; all patients received openlabel Viekira. Patients in both trials who received Viekira plus ribavirin achieved significantly higher SVR rates compared with patients who did not receive ribavirin. The only major difference between the two studies was that PEARL-III enrolled patients with HCV genotype 1b (n = 419) and PEARL-IV enrolled patients with HCV genotype 1a (n = 305). The majority of patients in both trials had mild-tomoderate liver fibrosis (stage F0T-F2). Among patients with HCV genotype 1b (PEARL-III), 99.0% (ribavirin-free group) and 99.5% (ribavirin-treated group) achieved an SVR. Only 1 patient in the ribavirin-free group experienced virological failure.
Similarly, among patients with HCV genotype 1a (PEARL-IV), 90.2% (ribavirin-free group) and 97.0% (ribavirin-treated group) achieved an SVR. 34 The difference in cure rates between the two groups was attributed to the greater number of virological failures experienced by patients not receiving ribavirin compared with those in the ribavirin-treated group (7.8% versus 2.0%). Eighteen patients with HCV genotype 1a had virological failure, 16 of whom were in the group not receiving ribavirin. Thus, the use of ribavirin in patients with HCV genotype 1a may confer additional benefit. The patients who experienced treatment failure had at least one amino acid variant that conferred resistance to one of the three components of the regimen. Furthermore, compared with HCV genotype 1b infection, HCV genotype 1a infection has been reported to have a lower barrier to resistance. 38, 39 The majority of adverse events were mild in all treatment groups. The results of PEARL-III and PEARL-IV demonstrated that 12 weeks of Viekira, with or without ribavirin, can achieve high response rates (overall SVR rates of ≥90%) for treatment-naive patients without cirrhosis.
SAPPHIRE-I. SAPPHIRE-I was a double-blind, placebo-controlled trial that enrolled 631 treatment-naive patients with HCV genotype 1 infection without cirrhosis. 35 Patients were randomized in a 3:1 ratio to receive Viekira with ribavirin (n = 473) or matching placebo (n = 158) for 12 weeks. Patients were stratified by HCV subtype (genotype 1a versus genotype 1b). After 12 weeks of the blinded study phase, the placebo group received Viekira with ribavirin for an additional 12 weeks (open-label treatment period). The SVR rates were slightly higher for patients with HCV genotype 1b compared with HCV genotype 1a (98% versus 95.3%, respectively). The overall SVR rate was 96.2% at 12 weeks after treatment completion (95% confidence interval [CI], 94.5-97.9%). The discontinuation rate due to adverse events was 0.6% in both groups. Eight patients with genotype 1a infection had at least one amino acid variant that conferred resistance to one of the three components of the regimen.
One patient had virological failure during treatment (0.2%), and 7 patients relapsed by posttreatment week 12 (1.5%). Data from SAPPHIRE-I reinforced the findings from the PEARL-III and PEARL-IV trials, showing that high SVR rates can be achieved with a 12-week treatment course of Viekira with ribavirin, especially for treatmentnaive, noncirrhotic patients with HCV genotype 1a infection.
SAPPHIRE-II. SAPPHIRE-II mirrored SAPPHIRE-I in study design. However, SAPPHIRE-II enrolled treatmentexperienced, noncirrhotic patients with HCV genotype 1 infection (n = 394). 36 Patients were stratified by HCV subtype (genotype 1a versus genotype 1b) and prior response to peginterferon alfa-ribavirin therapy (relapse, partial response, or null response). Patients were randomly assigned in a 3:1 ratio to receive Viekira with ribavirin (n = 297) or matching placebo (n = 97) during a 12-week double-blind period. After 12 weeks of the blinded study phase, the placebo group received Viekira with ribavirin for 12 weeks (open-label treatment period). SVR rateswere similar for patients with HCV genotype 1a and 1b infections (96.0% and 96.7%, respectively). Response rates were further evaluated based on patients' prior response to peginterferon-ribavirin (relapse [95.3%], partial response [100%], and null response [95.2%]). Seven patients (2.4%) experienced posttreatment relapse, 4 of whom had HCV genotype 1a; 1 patient had HCV genotype 1b. Relapse was associated with at least one amino acid variant that conferred resistance to one of the three components of the regimen. Three patients in the treatment group (1.0%) discontinued the regimen due to adverse events, such as elevated transaminase levels (grade 3), diarrhea, and acute renal failure (unrelated to the Viekira regimen). The overall mean SVR rate was 96.3% (95% CI, 94.2-98.4%). The findings from SAPPHIRE-II suggested that a 12-week course of Viekira plus ribavirin was effective for treatmentexperienced, noncirrhotic patients with HCV genotype 1, regardless of previous treatment failure with peginterferon alfa-ribavirin.
TURQUOISE-II. TURQUOISE-II was an open-label study that evaluated the efficacy of Viekira with ribavirin in 380 treatment-naive and treatmentexperienced patients with HCV genotype 1 who had compensated cirrhosis (Child-Pugh class A). 37 Patients were randomized in a 1:1 ratio to receive treatment for 12 weeks (n = 208) or 24 weeks (n = 172). Treatment-naive and treatment-experienced patients were stratified by HCV subtype (genotype 1a versus genotype 1b). Treatmentexperienced patients were further stratified based on their prior response to peginterferon alfa-ribavirin (relapse, partial response, or null response). Results showed that 191 patients in the 12-week group and 165 patients in the 24-week group) achieved similar SVR rates (91.8% and 95.9%, respectively; p = 0.09). Thirteen patients (6.2%) in the 12-week group had virological failure during the study or relapsed after treatment, compared with 4 patients (2.3%) in the 24-week group. Altogether, 12-week and 24-week treatment with Viekira plus ribavirin resulted in high SVR rates in patients with HCV genotype 1 and cirrhosis.
TURQUOISE-I. Viekira was also studied in special patient populations with HIV and HCV coinfection, who had undergone liver transplantation, and with advanced renal disease. 40 FDA approval of Viekira for HIV-HCV coinfected persons was based on the TURQUOISE-I trial. This Phase II/III, randomized, open-label, uncontrolled study evaluated the efficacy and safety of Viekira with ribavirin for 12 or 24 weeks. Study enrollment included 63 HIV patients coinfected with HCV genotype 1 who were HCV treatment naive or treatment experienced with peginterferon alfa-ribavirin. Nineteen percent of patients had compensated cirrhosis (Child-Pugh class A). Enrolled patients' HIV infection was stabilized with atazanavir-based or raltegravirbased antiretroviral regimens. For patients receiving ritonavir-boosted atazanavir, the ritonavir component was discontinued while they received Viekira with ribavirin. Atazanavir was administered with the morning dose of Viekira and ribavirin. The ritonavir component of the antiretroviral regimen was resumed after HCV therapy was completed. The SVR rates were similar for patients in the 12-and 24-week groups (94% and 91%, respectively; p > 0.99). Hence, treatment with Viekira plus ribavirin resulted in high SVR rates among patients coinfected with HCV genotype 1 and HIV.
CORAL-1. The efficacy and safety of Viekira were also studied in liver transplant recipients. 41 CORAL-1, a Phase II, open-label, single-group study, evaluated Viekira with ribavirin for 24 weeks. It enrolled 34 liver transplant patients (at least 12 months posttransplantation) who had HCV genotype 1 infection, normal hepatic function, and a fibrosis score of ≤2. Low-dose ribavirin (600-800 mg/day) was administered at the discretion of the study investigators. Patients received immunosuppressants (tacrolimus or cyclosporine with dosage modified by testing trough levels of calcineurin inhibitors) during treatment with Viekira. A SVR was achieved in 33 (97%) of 34 patients.
RUBY-1. The safety and efficacy of a 12-or 24-week course of Viekira, with or without ribavirin, were also evaluated in patients with chronic kidney disease. 32 
Drug resistance
A pooled analysis of over 2500 patients treated with Viekira, with or without ribavirin, in Phase IIb and III clinical trials revealed that 3% of patients (n = 74) who experienced virological failure had treatmentemergent resistance, primarily posttreatment relapse. [33] [34] [35] [36] 38, 39 Among 67 patients with HCV genotype 1, 50 had nonstructural 3 variants, 46 patients had nonstructural 5A variants, and 37 had nonstructural 5B variants. Treatment-emergent variants were observed in all three viral targets for 30 patients. In contrast, among 7 patients with HCV genotype 1b, 4 had nonstructural 3 variants, 2 had nonstructural 5A variants, and 1 had both nonstructural 3 and 5A variants. There were no patients with HCV genotype 1b who developed resistant variants in all three viral targets. The common variants reported were D168V and R155K (nonstructural 3/4A), M28T and Q30R (nonstructural 5A), and S556G (nonstructural 5B). [42] [43] Currently, for patients who develop virological failure and resistance when treated with Viekira, the impact on subsequent therapy with other nonstructural 3/4A, nonstructural 5A, or nonstructural 5B inhibitors remains unknown.
Drug-drug interactions
Drug-drug interactions are anticipated with Viekira, as paritaprevir and ritonavir are predominantly CYP3A4 substrates. Coadministration with either potent CYP3A4 inducers or inhibitors will notably reduce or increase the plasma concentrations of paritaprevir and ritonavir, respectively. Dasabuvir is predominantly a CYP2C8 substrate. When coadministered with CYP2C8 inhibitors, plasma dasabuvir concentrations will appreciably increase. 31, 44 On the other hand, coadministration of paritaprevir, ritonavir, and dasabuvir with potent CYP2C8 inducers may reduce plasma concentrations of paritaprevir, ritonavir, and dasabuvir. Ombitasvir, paritaprevir, ritonavir, and dasabuvir are substrates of the Pglycoprotein transporter. In addition, ombitasvir, paritaprevir, and dasabuvir are substrates of the breast cancer resistance protein (BCRP) transporter. Paritaprevir is a substrate of membrane transport proteins called organic anion-transporting polypeptides (OATP) 1B1 and 1B3. 44, 45 Therefore, coadministration with inhibitors of P-glycoprotein, BCRP, OATP1B1 or OATP1B3 may increase the plasma concentrations of the individual components of the regimen. Aside from being metabolized via hydrolysis, oxidation, or CYP450 enzymes, ombitasvir, paritaprevir, ritonavir, and dasabuvir are also inhibitors of various transporters and CYP3A4. Ombitasvir, paritaprevir, and dasabuvir are inhibitors of uridine diphosphate glucuronosyltransferase 1 polypeptide A1. Paritaprevir, dasabuvir, and ritonavir also inhibit BCRP. Furthermore, paritaprevir inhibits OATP1B1 and OATP1B3. 44, 45 Ritonavir is also a potent inhibitor of CYP3A4. In summary, coadministration of Viekira is contraindicated with drugs that are (1) potent CYP3A or CYP2C8 inducers, (2) potent CYP2C8 inhibitors, or (3) highly dependent on CYP3A for clearance.
Coadministration of Viekira with HIV antiretrovirals such as darunavirritonavir, lopinavir-ritonavir, and rilpivirine is not recommended. 46 When Viekira is coadministered with an HIV regimen containing atazanavir, atazanavir should be taken in the morning without additional ritonavir. Coadministration with drug classes such as antifungals, immunosuppressants (cyclosporine, tacrolimus), particular hydoxymethylglutaryl-coenzyme A reductase inhibitors (rosuvastatin, pravastatin), omeprazole, or salmeterol requires close monitoring and dosage adjustments. 44 When Viekira is coadministered with ribavirin, the warnings, precautions, and contraindications to ribavirin also apply. Table 1 summarizes the drugs that are contraindicated with Viekira coadministration.
Safety and tolerability
Treatment with Viekira is generally safe and well tolerated. 27, 28 The most frequently reported adverse effects (≥5% of patients) associated with Viekira without ribavirin were nausea, pruritus, and insomnia. [33] [34] [35] [36] 48 During clinical trials, the most common adverse effects (≥10%) among patients receiving Viekira with ribavirin were fatigue, nausea, pruritus, insomnia, and weakness. [33] [34] [35] [36] [37] 40 Temporary mildto-moderate anemia was more commonly associated with ribavirin as an adverse effect; reductions in the dosage of ribavirin may help alleviate adverse effects associated with anemia. 48 Mild, self-limiting, rash-related events were also reported during the trials, especially in patients treated with ribavirin-containing regimens. [33] [34] [35] [36] 49 No serious cutaneous reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, or drug rash with eosinophilia and systemic symptoms, were reported.
Place in therapy
Viekira is approved only for the treatment of HCV genotype 1 infection in the United States. It is coadministered with ribavirin for patients infected with HCV genotype 1a, with or without compensated cirrhosis, and for patients with HCV genotype 1b with compensated cirrhosis. Viekira can be administered without ribavirin for patients with HCV genotype 1b who do not have cirrhosis. It is not recommended for patients who have not responded to (1) triple therapy with peginterferon alfa-ribavirin plus an HCV protease inhibitor or (2) a sofosbuvir-containing regimen. 49 More importantly, Viekira is effective and safe for patients who have undergone liver transplantation, are coinfected with HIV, or have advanced kidney disease. Table 2 illustrates the recommended Viekira regimens for patients with HCV genotype 1 infection, with HIV coinfection, and who have undergone liver transplantation. Close monitoring of drug-drug interactions is recommended at baseline and during Viekira therapy when it is coadministered with potent inhibitors and inducers of CYP3A4 and CYP2C8. The pill burden of Viekira may be an issue, as the regimen requires the administration of four pills daily, not including ribavirin. The therapy, however, is relatively cost-effective compared with more-expensive combination regimens, such as ledipasvir-sofosbuvir and simeprevir-sofosbuvir. The approximate costs for twelve weeks of therapy with Viekira, ledipasvirsofosbuvir, and simeprevir-sofosbuvir are $83,319, $94,500, and $150,000, respectively.
50,51

Conclusion
Viekira, the first coformulated direct-acting antiviral that targets different stages of the HCV life cycle, is an interferon-free treatment for HCV genotype 1 infection. It is associated with a virological cure rate of ≥90% and treatment durations of 12 and 24 weeks. Viekira is also effective Population includes treatment-naive and treatment-experienced patients who did not respond to prior treatment with peginterferon-ribavirin. HCV = hepatitis C virus, HIV = human immunodeficiency virus. b Viekira plus ribavirin for 12 weeks may be considered for treatment-naive patients or patients who had prior relapse or partial response to prior therapy with peginterferon-ribavirin. c Treatment duration is 24 weeks, regardless of HCV genotype 1 subtype. Dosage adjustments are required with cyclosporine or tacrolimus due to drug interactions. 41 and safe for patients who have undergone liver transplantation, are coinfected with HIV, or have advanced kidney disease.
